Advanced Gastric Cancer

CE / CME

Cases and Challenges in the Optimal Treatment of Advanced Gastric Cancer

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: April 27, 2023

Expiration: April 26, 2024

Activity

Progress
1
Course Completed

Please answer the questions below:

Which of the following biomarkers should be assessed in all patients with newly diagnosed advanced GC to inform initial systemic therapy recommendations?

For what level of PD-L1 expression is the chemotherapy + trastuzumab + pembrolizumab regimen indicated in HER2-positive advanced GC?

What is the most appropriate next step with T-DXd if grade 2 interstitial lung disease (ILD) is suspected?

After participating in this activity, how often do you plan to consider using chemotherapy + nivolumab as first-line treatment for HER2-negative advanced GC?

After participating in this activity, how often do you plan to test for dMMR/MSI-H status in patients with suspected mGC?

After participating in this activity, how often do you plan to counsel patients treated with T-DXd to report any symptoms of ILD?

Gary has HER2+ mGC, with PD-L1 CPS ≤1, TMB-low, and no actionable mutations. He has progressed after 1L chemoimmunotherapy + trastuzumab and has grade 2 neuropathy. What is the recommended next treatment?

David, age 65, is diagnosed with  HER2-negative mGC. In current guidelines, which of these PD-L1 levels would make chemotherapy + nivolumab a Category 1 recommendation for initial therapy?

At 2 months on CT + nivolumab, David has a partial response. Regular on-treatment monitoring reveals primary hypothyroidism. Which of the following approaches would you recommend for David?